Document is current
Any future updates will be listed below
-
Authors
Tajan, Mylène
Hennequart, Marc
Cheung, Eric C.
Zani, Fabio
Hock, Andreas K.
Legrave, Nathalie
Maddocks, Oliver D. K. https://orcid.org/0000-0002-5551-9091
Ridgway, Rachel A.
Athineos, Dimitris https://orcid.org/0000-0001-5298-7941
Suárez-Bonnet, Alejandro https://orcid.org/0000-0003-0296-5896
Ludwig, Robert L.
Novellasdemunt, Laura
Angelis, Nikolaos
Li, Vivian S. W. https://orcid.org/0000-0003-2041-0085
Vlachogiannis, Georgios
Valeri, Nicola
Mainolfi, Nello
Suri, Vipin
Friedman, Adam
Manfredi, Mark
Blyth, Karen https://orcid.org/0000-0002-9304-439X
Sansom, Owen J. https://orcid.org/0000-0001-9540-3010
Vousden, Karen H. https://orcid.org/0000-0002-7365-1766
-
Funding
Funding for this research was provided by:
Cancer Research UK (C596/A10419, C596/A26855, FC0010557)
RCUK | Medical Research Council (FC0010557)
Wellcome Trust (FC0010557)
- License Information
-
More Information
Article History
Received: 1 October 2019
Accepted: 18 November 2020
First Online: 14 January 2021
Competing interests
: K.H.V. is on the Board of Directors and shareholder of Bristol Myers Squibb, a shareholder of GRAIL Inc and on the Science Advisory Board (with stock options) of PMV Pharma, RAZE Therapeutics and Volastra Therapeutics. She is also on the SAB of Ludwig Cancer. K.H.V. is a co-founder and consultant of Faeth Therapeutics, funded by Khosla Ventures. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to CRUK Cancer Research Technology filing of Patent Application WO/2017/144877. N.V. received honoraria or travel accommodation from Merck Serono, Pfizer, Bayer, Eli-Lilly and Menarini Silicon Biosystems. V.S., N.M., A.F. and M.M. are shareholders of RAZE Therapeutics, Inc. All other authors declare no competing interests.
